Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manish Monga

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Oral Oncology|September 24, 2017
A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141Naomi Kiyota, Yasuhisa Hasegawa, Shunji Takahashi, et al.
The Lancet. Oncology|January 14, 2022
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 studyArlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, et al.
The Oncologist|June 6, 2018
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L Gillison, George Blumenschein, Jerome Fayette, et al.
The New England Journal of Medicine|October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
The Lancet. Oncology|June 28, 2017
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J Harrington, Robert L Ferris, George Blumenschein, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Oral Oncology|September 24, 2017
A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141Naomi Kiyota, Yasuhisa Hasegawa, Shunji Takahashi, et al.
The Lancet. Oncology|January 14, 2022
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 studyArlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, et al.
The Oncologist|June 6, 2018
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L Gillison, George Blumenschein, Jerome Fayette, et al.
The New England Journal of Medicine|October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
The Lancet. Oncology|June 28, 2017
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J Harrington, Robert L Ferris, George Blumenschein, et al.
Pageof 2